Technical Perspectives: Antibody Drug Conjugates

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-12-07-2011
Volume 7
Issue 12

A podcast moderated by Patricia Van Arnum, executive editor of Pharmaceutical Technology.

Antibody drug conjugates represent a niche area of drug development. Antibody drug conjugates combine a small-molecule, often a cytotoxic compound, to a monoclonal antibody. Grant E. Boldt, PhD, director of European business development for SAFC, discusses manufacturing considerations in producing antibody drug conjugates with Patricia Van Arnum, executive editor of Pharmaceutical Technology. Listen to the podcast.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content